Go Pro

Doug Schenkel Analyst Performance

Analyst at UBS Group

Doug Schenkel is a stock analyst at UBS Group in the healthcare sector, covering 19 publicly traded companies. Over the past year, Doug Schenkel has issued 16 stock ratings, including buy and hold recommendations. While full access to Doug Schenkel's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Doug Schenkel's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
34 Last 11 Years
Buy Recommendations
75.76% 25 Buy Ratings
Companies Covered
19 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.8%25 ratings
Hold24.2%8 ratings
Sell0.0%0 ratings

Out of 33 total stock ratings issued by Doug Schenkel at UBS Group, the majority (75.8%) have been Buy recommendations, followed by 24.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
57.9% of companies on NASDAQ
11 companies
NYSE
42.1% of companies on NYSE
8 companies

Doug Schenkel, an analyst at UBS Group, currently covers 19 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
19 companies
100.0%

Doug Schenkel of UBS Group specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
LIFE SCIENCES TOOLS & SERVICES
12 companies
63.2%
BIOTECHNOLOGY
2 companies
10.5%
HEALTHCARE EQUIPMENT & SUPPLIES
2 companies
10.5%
HEALTHCARE PROVIDERS & SERVICES
2 companies
10.5%
HEALTHCARE TECHNOLOGY
1 company
5.3%

Doug Schenkel's Ratings History at UBS Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Heartflow, Inc. stock logo
HTFL
Heartflow
9/9/2026Initiated Coverage$47.75$55.00Neutral
GRAIL, Inc. stock logo
GRAL
GRAIL
9/9/2026Initiated Coverage$79.10$105.00Buy
Caris Life Sciences, Inc. stock logo
CAI
Caris Life Sciences
9/9/2026Initiated Coverage$24.82$28.00Neutral
Illumina, Inc. stock logo
ILMN
Illumina
9/9/2026Initiated Coverage$211.06$260.00Buy
Waters Corporation stock logo
WAT
Waters
9/9/2026Initiated Coverage$408.52$490.00Buy
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
9/9/2026Boost Price Target$339.55$415.00Buy
Revvity Inc. stock logo
RVTY
Revvity
9/9/2026Initiated Coverage$122.45$140.00Neutral
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
9/9/2026Initiated Coverage$1.31$1.35Neutral
Natera, Inc. stock logo
NTRA
Natera
9/9/2026Boost Price Target$325.80$435.00Buy
Mettler-Toledo International, Inc. stock logo
MTD
Mettler-Toledo International
9/9/2026Initiated Coverage$1,299.83$1,460.00Neutral
Tempus AI, Inc. stock logo
TEM
Tempus AI
9/9/2026Initiated Coverage$64.29$70.00Neutral
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
9/9/2026Initiated Coverage$128.06$144.00Neutral
Thermo Fisher Scientific Inc. stock logo
TMO
Thermo Fisher Scientific
9/8/2026Upgrade$603.43$730.00Buy
Bruker Corporation stock logo
BRKR
Bruker
12/10/2025Upgrade$45.36$60.00Outperform
Waters Corporation stock logo
WAT
Waters
12/10/2025Upgrade$386.16$480.00Outperform
Guardant Health, Inc. stock logo
GH
Guardant Health
9/25/2025Upgrade$57.67$75.00Outperform